Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04611633Terminated

Study in COPD Patients Evaluating the Quality of Life (TRISNOOZE)

Role: lead

NCT03627858Completed

Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting

Role: lead

NCT04246060Enrolling By Invitation

Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients

Role: lead

NCT04526431Recruiting

Tacrolimus Pharmacokinetic Subpopulations

Role: collaborator

NCT04246931Unknown

Adherence Evaluation in COPD

Role: lead

All 5 trials loaded